Drug intelligence / Profile preview

IGCAR

Development stage
Preclinical
Lead developer
Ingenium Therapeutics
Modality
CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

IGCAR is a preclinical-stage, 5th generation in vivo chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Ingenium Therapeutics. Unlike traditional ex vivo CAR therapies that require complex laboratory modification of extracted cells, IGCAR utilizes a proprietary Polyplex mRNA delivery system to deliver CAR-encoding mRNA directly into the patient's endogenous natural killer cells. This approach aims to induce CAR expression in vivo, potentially simplifying the manufacturing process and increasing accessibility. The therapy is currently being investigated for the treatment of various solid tumors, although the specific CAR target has not been publicly disclosed.

Other names
in vivo CAR-NK
02

Targets

TF antigen (Thomsen-Friedenreich antigen)

Beyond the preview

Go deeper on IGCAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGCAR.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call